ArticleOncoTargets and therapy2018
Comparison of detection methods of
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.The clinical respiratory journal · 2024Pooled it
- Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.Future oncology (London, England) · 2025Article
- A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer.Translational oncology · 2024Article
- High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid.Japanese journal of clinical oncology · 2024Article
- Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.Cancers · 2023Article
- Article
- Leptomeningeal Metastatic L858ROncoTargets and therapy · 2022Article
- Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.Therapeutic advances in medical oncology · 2021Article
- Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel.Human cell · 2020Article
- Article
- Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.BMC cancer · 2020Article
- Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning.Cancer medicine · 2019Article
- The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.OncoTargets and therapy · 2019Article
- Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.Respiratory medicine case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against PATIENTS AND
methodsWe prospectively evaluated the sensitivity, specificity, and parallelism of the detection of
resultsFifteen patients were enrolled. In 10 patients whose
conclusionPlasma, serum, and tissue genotyping can have complementary roles for detecting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.